Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Control of Metastases via Myeloid CD39 and NK Cell Effector Function.

Yan J, Li XY, Roman Aguilera A, Xiao C, Jacoberger-Foissac C, Nowlan B, Robson SC, Beers C, Moesta AK, Geetha N, Teng MWL, Smyth MJ.

Cancer Immunol Res. 2020 Jan 28. doi: 10.1158/2326-6066.CIR-19-0749. [Epub ahead of print]


Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A, Jacoberger-Foissac C, Wong C, Dela Cruz T, Welch M, Lerner AG, Spatola BN, Soros VB, Corbin J, Anderson AC, Effern M, Hölzel M, Robson SC, Johnston RL, Waddell N, Smith C, Bald T, Geetha N, Beers C, Teng MWL, Smyth MJ.

Cancer Discov. 2019 Dec;9(12):1754-1773. doi: 10.1158/2159-8290.CD-19-0541. Epub 2019 Nov 7.


Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade.

Moesta AK, Cooke K, Piasecki J, Mitchell P, Rottman JB, Fitzgerald K, Zhan J, Yang B, Le T, Belmontes B, Ikotun OF, Merriam K, Glaus C, Ganley K, Cordover DH, Boden AM, Ponce R, Beers C, Beltran PJ.

Clin Cancer Res. 2017 Oct 15;23(20):6190-6202. doi: 10.1158/1078-0432.CCR-17-0681. Epub 2017 Jul 13.


The production of KIR-Fc fusion proteins and their use in a multiplex HLA class I binding assay.

Hilton HG, Moesta AK, Guethlein LA, Blokhuis J, Parham P, Norman PJ.

J Immunol Methods. 2015 Oct;425:79-87. doi: 10.1016/j.jim.2015.06.012. Epub 2015 Jun 19.


Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3.

Moesta AK, Parham P.

Front Immunol. 2012 Nov 22;3:336. doi: 10.3389/fimmu.2012.00336. eCollection 2012.


Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.

Hilton HG, Vago L, Older Aguilar AM, Moesta AK, Graef T, Abi-Rached L, Norman PJ, Guethlein LA, Fleischhauer K, Parham P.

J Immunol. 2012 Aug 1;189(3):1418-30. doi: 10.4049/jimmunol.1100431. Epub 2012 Jul 6.


Human-specific evolution and adaptation led to major qualitative differences in the variable receptors of human and chimpanzee natural killer cells.

Abi-Rached L, Moesta AK, Rajalingam R, Guethlein LA, Parham P.

PLoS Genet. 2010 Nov 4;6(11):e1001192. doi: 10.1371/journal.pgen.1001192.


Coevolution of killer cell Ig-like receptors with HLA-C to become the major variable regulators of human NK cells.

Older Aguilar AM, Guethlein LA, Adams EJ, Abi-Rached L, Moesta AK, Parham P.

J Immunol. 2010 Oct 1;185(7):4238-51. doi: 10.4049/jimmunol.1001494. Epub 2010 Aug 30.


Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I.

Moesta AK, Graef T, Abi-Rached L, Older Aguilar AM, Guethlein LA, Parham P.

J Immunol. 2010 Oct 1;185(7):4233-7. doi: 10.4049/jimmunol.1001951. Epub 2010 Aug 27.


Primate-specific regulation of natural killer cells.

Parham P, Abi-Rached L, Matevosyan L, Moesta AK, Norman PJ, Older Aguilar AM, Guethlein LA.

J Med Primatol. 2010 Aug;39(4):194-212. doi: 10.1111/j.1600-0684.2010.00432.x. Review.


KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C.

Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM, Gleimer M, Hammond JA, Guethlein LA, Bushnell DA, Robinson PJ, Parham P.

J Exp Med. 2009 Oct 26;206(11):2557-72. doi: 10.1084/jem.20091010.


Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands.

Gendzekhadze K, Norman PJ, Abi-Rached L, Graef T, Moesta AK, Layrisse Z, Parham P.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18692-7. doi: 10.1073/pnas.0906051106. Epub 2009 Oct 16.


Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes.

Norman PJ, Abi-Rached L, Gendzekhadze K, Hammond JA, Moesta AK, Sharma D, Graef T, McQueen KL, Guethlein LA, Carrington CV, Chandanayingyong D, Chang YH, Crespí C, Saruhan-Direskeneli G, Hameed K, Kamkamidze G, Koram KA, Layrisse Z, Matamoros N, Milà J, Park MH, Pitchappan RM, Ramdath DD, Shiau MY, Stephens HA, Struik S, Tyan D, Verity DH, Vaughan RW, Davis RW, Fraser PA, Riley EM, Ronaghi M, Parham P.

Genome Res. 2009 May;19(5):757-69. doi: 10.1101/gr.085738.108.


Chimpanzees use more varied receptors and ligands than humans for inhibitory killer cell Ig-like receptor recognition of the MHC-C1 and MHC-C2 epitopes.

Moesta AK, Abi-Rached L, Norman PJ, Parham P.

J Immunol. 2009 Mar 15;182(6):3628-37. doi: 10.4049/jimmunol.0803401.


Evolution and survival of marine carnivores did not require a diversity of killer cell Ig-like receptors or Ly49 NK cell receptors.

Hammond JA, Guethlein LA, Abi-Rached L, Moesta AK, Parham P.

J Immunol. 2009 Mar 15;182(6):3618-27. doi: 10.4049/jimmunol.0803026.


Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.

Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P.

J Immunol. 2008 Mar 15;180(6):3969-79.


Peptide register shifting within the MHC groove: theory becomes reality.

Bankovich AJ, Girvin AT, Moesta AK, Garcia KC.

Mol Immunol. 2004 Feb;40(14-15):1033-9. Review.


T cell receptor Beta chain gene usage in endemic pemphigus foliaceus (fogo selvagem).

Moesta AK, Lin MS, Diaz LA, Sinha AA.

J Invest Dermatol. 2002 Aug;119(2):377-83.

Supplemental Content

Loading ...
Support Center